Literature DB >> 11216927

Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy.

S Suarez1, L Baril, B Stankoff, M Khellaf, B Dubois, C Lubetzki, F Bricaire, J J Hauw.   

Abstract

OBJECTIVE: To examine the impact of highly active antiretroviral therapy (HAART) on the outcome of HIV-1-related cognitive impairments using a neuropsychological (NP) battery to assess separately the psychomotor, executive function and memory fields.
DESIGN: A longitudinal study of HIV-1-infected patients based on serial NP tests in a Paris University Hospital.
METHODS: A group of 91 HIV-1-infected patients, of whom 47 were already taking HAART at their first NP examination, were initially categorized as cognitively impaired (n = 53) or non-impaired (n = 38) and underwent one to six serial NP batteries (mean follow-up 12.3+/-8.3 months). Generalized estimating equations (GEE) were used to evaluate performance in a given NP test according to the number of days on HAART.
RESULTS: Despite a 25% mortality rate among patients who had cognitive impairment at their first NP examination, GEE showed a positive relationship between the duration of HAART and cognitive performance. Performance in psychomotor tests (e.g. Purdue Pegboard dominant hand) improved continuously during the study period, while memory test performance (e.g. Grober and Buschke free recall) tended to reach a plateau.
CONCLUSIONS: HAART improves subcortical cognitive functions during the first year of treatment. Distinct neuropathological mechanisms appear to underlie psychomotor and memory dysfunctions in AIDS.

Entities:  

Mesh:

Year:  2001        PMID: 11216927     DOI: 10.1097/00002030-200101260-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons.

Authors:  David J Moore; Miguel Arce; Suzanne Moseley; J Allen McCutchan; Jennifer Marquie-Beck; Donald R Franklin; Florin Vaida; Cristian L Achim; Justin McArthur; Susan Morgello; David M Simpson; Benjamin B Gelman; Ann C Collier; Christina M Marra; David B Clifford; Robert K Heaton; Igor Grant
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

2.  Reward, attention, and HIV-related risk in HIV+ individuals.

Authors:  Brian A Anderson; Sharif I Kronemer; Jessica J Rilee; Ned Sacktor; Cherie L Marvel
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

3.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

4.  Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS.

Authors:  Mark L Ettenhofer; Jessica Foley; Steven A Castellon; Charles H Hinkin
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

5.  Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.

Authors:  Sandra A Springer; Shu Chen; Frederick Altice
Journal:  AIDS Care       Date:  2009-08

Review 6.  Does highly active antiretroviral therapy improve neurocognitive function? A systematic review.

Authors:  John A Joska; Hetta Gouse; Robert H Paul; Dan J Stein; Alan J Flisher
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

7.  The CD28/HLA-DR expressions on CD4+T but not CD8+T cells are significant predictors for progression to AIDS.

Authors:  Byeong-Sun Choi; Yong-Keun Park; Joo-Shil Lee
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

8.  Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.

Authors:  Lucette A Cysique; Paul Maruff; Bruce J Brew
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

9.  Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.

Authors:  Robert C Kalayjian; Kunling Wu; Scott Evans; David B Clifford; Muraldihar Pallaki; Judith S Currier; Marlene Smryzynski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

10.  Cognitive performance and the thymus among HIV-infected subjects receiving HAART.

Authors:  Maria J Miguez-Burbano; John E Lewis; Jose Moreno; Joel Fishman
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.